Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 6.53% is 65% above its 5-year average of 3.97%, near the high end of its 5-year range (0.00%–6.86%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.26% below its 12-month average of 6.61%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 6.53%.
DEBT TO ASSETS RATIO
6.53%
DEBT TO ASSETS RATIO AVG TTM
6.61%
DEBT TO ASSETS RATIO AVG 3Y
5.32%
DEBT TO ASSETS RATIO AVG 5Y
3.97%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-1.26%
CURRENT VS 3Y AVG
+22.85%
CURRENT VS 5Y AVG
+64.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 580 covered companies
CURRENT VS SECTOR MEDIAN
+6430.92%
vs the sector median at left
Castle Biosciences, Inc.
Market Cap
$1.06B
Debt to Assets Ratio
6.53%
TTM Avg
6.61%
3Y Avg
5.32%
5Y Avg
3.97%
Market Cap
$1.03B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Debt to Assets Ratio
0.54%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.09B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10B
Debt to Assets Ratio
0.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.00B
Debt to Assets Ratio
0.57%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.00B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Castle Biosciences, Inc. (CSTL) | $1.06B | 6.53% | 6.61% | 5.32% | 3.97% |
| Teladoc Health, Inc. (TDOC)vs › | $1.03B | 0.38% | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 0.54% | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.09B | 0.00% | N/A | N/A | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.10B | 0.00% | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | 0.03% | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.10B | 0.39% | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.00B | 0.57% | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | 0.01% | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $999.53M | 0.02% | N/A | N/A | N/A |
Debt/Assets
6.5%
Debt/Equity
0.08
Current Ratio
6.04
Interest Coverage
-497.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 6.53% |
| 2026-03-31 | 6.70% |
| 2025-12-31 | 6.38% |
| 2025-09-30 | 6.60% |
| 2025-06-30 | 6.86% |
| 2025-03-31 | 5.15% |
| 2024-12-31 | 4.96% |
| 2024-09-30 | 5.20% |
| 2024-06-30 | 5.17% |
| 2024-03-31 | 5.46% |
| 2023-12-31 | 3.38% |
| 2023-09-30 | 3.33% |
| 2023-06-30 | 3.38% |
| 2023-03-31 | 3.02% |
| 2022-12-31 | 3.00% |
| 2022-09-30 | 2.93% |
| 2022-06-30 | 1.68% |
| 2022-03-31 | 1.78% |
| 2021-12-31 | 1.77% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 10.67% |
| 2020-06-30 | 12.28% |
| 2020-03-31 | 21.08% |
| 2019-12-31 | 20.98% |
| 2019-09-30 | 22.00% |
| 2019-06-30 | 87.32% |
| 2019-03-31 | 76.32% |
| 2018-12-31 | 109.35% |
